Incretin Atlas › Molecules
Molecules
57 incretin-based agents and amylin analogues. Each page lists trial arms, outcome trials, registered trials, label indications and primary sources.
| Molecule | Mechanism | Route | Company | Stage | Status | Arms |
|---|---|---|---|---|---|---|
| Danuglipron PF-06882961, Pfizer | GLP-1 (small molecule) | oral | Pfizer | stopped | Discontinued (2025, liver safety signal) | 0 |
| Beinaglutide Benemae | GLP-1 | s.c. daily | Benemae | approved | Approved in China: T2D (2016), weight management (2023) | 1 |
| Ecnoglutide XW003 | GLP-1 (biased agonist) | s.c. | Sciwind | approved | Approved in China: T2D (January 2026) and weight management (March 2026); SLIMMER published (Lancet Diabetes Endocrinol 2025) | 8 |
| Efsubaglutide alfa (supaglutide) Yinnuo / Innogen | GLP-1 | s.c. weekly | Yinnuo (Innogen) | approved | Approved in China for T2D (January 2025); obesity phase 2b ENLIGHT positive; obesity phase 3 topline expected end-2026 | 5 |
| Liraglutide Saxenda / generics | GLP-1 | s.c. daily | Novo Nordisk / generics | approved | Approved for obesity (2014); generics available | 0 |
| Mazdutide IBI362 | GLP-1/GCG | s.c. | Innovent (Lilly licence) | approved | Approved in China: obesity (June 2025) and T2D (September 2025); 9 mg supplementary NDA accepted (Nov 2025); GLORY-2 published (JAMA 2026) | 11 |
| Orforglipron LY3502970 | GLP-1 (small molecule) | oral | Eli Lilly | approved | Approved in the US for obesity (Foundayo, 2026); T2D phase 3 positive (ACHIEVE) | 12 |
| PB-119 PegBio (PEGylated exenatide) | GLP-1 | s.c. weekly | PegBio | approved | Approved in China for T2D (November 2025) | 2 |
| PEG-loxenatide Hansoh (Fulaimei) | GLP-1 | s.c. weekly | Hansoh | approved | Approved in China for T2D (May 2019, Fulaimei) | 4 |
| Semaglutide Wegovy / Ozempic / Rybelsus | GLP-1 | s.c. / oral | Novo Nordisk | approved | Approved: obesity, T2D, MACE reduction, CKD in T2D (Ozempic), MASH (Wegovy US 2025; Kayshild EU 2026); oral Wegovy tablets | 5 |
| Tirzepatide Zepbound / Mounjaro | GIP/GLP-1 | s.c. | Eli Lilly | approved | Approved: obesity, T2D, obstructive sleep apnoea (FDA); MACE reduction added to the Mounjaro US label (2026) | 7 |
| BGM0504 BrightGene | GIP/GLP-1 | s.c. | BrightGene | filed | Phase 3 positive in China (52 weeks, up to −19.2 %); NDA accepted (June 2026) | 6 |
| HDM1702 Zhongmei Huadong | GLP-1 | s.c. | Huadong Medicine | filed | Semaglutide follow-on: phase 3 equivalence to Wegovy; NDAs accepted in China (T2D Mar 2025; weight Apr 2026) | 1 |
| HRS-7535 Hengrui | GLP-1 (small molecule) | oral | Hengrui | filed | Phase 3 positive: OUTSTAND-1/-2 (T2D), HARBOR-1 (obesity); NDAs accepted in China for T2D and weight management (Sep 2026) | 9 |
| HS-20094 Hansoh (Regeneron licence ex-China) | GIP/GLP-1 | s.c. | Hansoh | filed | Olatorepatide. Phase 3 LIGHTEN positive in China (−18.7 % at 48 weeks, EASD 2026); NDA accepted (June 2026); Regeneron licence ex-China | 3 |
| Ribupatide (HRS9531) KAI-9531, Hengrui / Kailera | GIP/GLP-1 | s.c. | Hengrui / Kailera | filed | Phase 3 positive in China (GEMINI-1: −17.7 % TP / −19.2 % at 48 weeks); NDA accepted in China (Sep 2025); global phase 3 KaiNETIC enrolled (Kailera) | 16 |
| TG103 CSPC | GLP-1 | s.c. | CSPC | filed | Efmedaglutide alfa. Phase 3 T2D non-inferior to dulaglutide; obesity NDA accepted in China (Oct 2025) | 2 |
| ASC30 Ascletis (oral small molecule and injectable) | GLP-1 (small molecule) | oral / s.c. | Ascletis | phase 3 | Oral phase 2 (13 weeks: placebo-adjusted −7.7 %); global phase 3 AURORA started (Aug 2026) | 0 |
| AZD5004 (ECC5004) Eccogene → AstraZeneca | GLP-1 (small molecule) | oral | AstraZeneca (Eccogene) | phase 3 | Elecoglipron. Phase 2b VISTA (obesity) and SOLSTICE (T2D) positive; phase 3 started (June 2026) | 11 |
| Aleniglipron GSBR-1290, Structure Therapeutics | GLP-1 (small molecule) | oral | Structure Therapeutics | phase 3 | Two pivotal phase 3 trials (obesity; obesity with or without T2D) recruiting since Jul 2026; phase 2b ACCESS reported 2025 | 3 |
| Amycretin zenagamtide | GLP-1 + amylin (unimolecular) | s.c. / oral | Novo Nordisk | phase 3 | Phase 3 (AMAZE) started | 6 |
| Berobenatide (MET-097i) Metsera (Pfizer) | GLP-1 (ultra-long-acting, monthly) | s.c. monthly | Pfizer (Metsera) | phase 3 | Phase 3 started 2026 (monthly dosing); phase 2b VESPER reported 2025 | 0 |
| Bofanglutide (GZR18) Gan & Lee | GLP-1 | s.c. every 2 weeks | Gan & Lee | phase 3 | Phase 3 GRADUAL-1 positive (48 mg every 2 weeks: −18.5 % at 52 weeks); US phase 2; once-monthly GRADUAL-3 started | 12 |
| CT-388 Roche / Carmot | GIP/GLP-1 | s.c. | Roche | phase 3 | Phase 3 (Enith1, Enith2 and a third trial) recruiting since Mar 2026; phase 2 (48 weeks) presented at EASD 2026 | 2 |
| CagriSema cagrilintide + semaglutide | GLP-1 + amylin | s.c. | Novo Nordisk | phase 3 | Phase 3 (REDEFINE); filing 2026 | 6 |
| DR10624 Zhejiang Doer Biologics | GLP-1/GCG/FGF21 | s.c. | Doer Biologics | phase 3 | Phase 3 in severe hypertriglyceridaemia; obesity/MASH in development | 0 |
| EloraTZP eloralintide + tirzepatide, Eli Lilly | GIP/GLP-1 + amylin | s.c. | Eli Lilly | phase 3 | Phase 2b in obesity with T2D positive (Sep 2026: up to −23.3 % vs −14.8 % with tirzepatide 15 mg); phase 3 AMPLIFY-1 and AMPLIFY-2 registered (100 weeks, start Q4 2026) | 4 |
| Eloralintide LY3841136 | Amylin | s.c. | Eli Lilly | phase 3 | Phase 3 ENLIGHTEN programme recruiting since Dec 2025 (obesity, T2D, sleep apnoea, knee osteoarthritis, maintenance after incretin therapy); phase 2 complete | 3 |
| HDM1002 Zhongmei Huadong | GLP-1 (small molecule) | oral | Huadong Medicine | phase 3 | Phase 3 HDM1002-301 positive (oral; up to −12.2 % efficacy estimand at 52 weeks); pre-NDA | 2 |
| HDM1005 Huadong | GIP/GLP-1 | s.c. | Huadong Medicine | phase 3 | Phase 3 in China (obesity; T2D; head-to-head vs mazdutide in T2D) since Oct 2025; phase 2 T2D (20 wk) at EASD 2026: HbA1c up to −2.57 % | 3 |
| Lenbelintide AZD6234, AstraZeneca | Amylin | s.c. | AstraZeneca | phase 3 | Phase 3 recruiting (adjunct to incretin-based therapy, 68 weeks) | 0 |
| MariTide maridebart cafraglutide | GLP-1 + GIPR antagonist (antibody) | s.c. monthly | Amgen | phase 3 | Phase 3 (MARITIME) | 9 |
| Noiiglutide SHR20004 / HS-20004, Hengrui | GLP-1 | s.c. | Hengrui | phase 3 | Phase 3 in T2D (China) completed; results not yet public | 0 |
| Pemvidutide ALT-801 | GLP-1/GCG | s.c. | Altimmune | phase 3 | Phase 3 PERFORMA in MASH recruiting since Jul 2026; phase 2 MOMENTUM (obesity) and IMPACT (MASH) complete | 1 |
| Petrelintide ZP8396 | Amylin | s.c. | Zealand / Roche | phase 3 | Phase 3 ZUPREME programme (ZUPREME-3, -4, -5) initiated with Roche; phase 2 ZUPREME-1 published (Lancet Diabetes Endocrinol 2026), ZUPREME-2 topline in T2D (Oct 2026) | 6 |
| RAY1225 Raynovent | GIP/GLP-1 | s.c. every 2 weeks | Raynovent | phase 3 | Phase 3 REBUILDING-2 positive (9 mg every 2 weeks: −22.2 % at 52 weeks, topline Oct 2026); licensed to Qilu | 9 |
| Retatrutide LY3437943 | GIP/GLP-1/GCG | s.c. | Eli Lilly | phase 3 | Phase 3 positive: TRIUMPH-1 (NEJM 2026), TRIUMPH-2/-3 and TRIUMPH-4 toplines; TRANSCEND-T2D-1 at EASD 2026 | 15 |
| Survodutide BI 456906 | GLP-1/GCG | s.c. | Boehringer Ingelheim / Zealand | phase 3 | Phase 3 positive in obesity (SYNCHRONIZE-1, NEJM 2026) and T2D (SYNCHRONIZE-2, NEJM 2026); SYNCHRONIZE-CVOT showed CV safety (non-inferior to placebo, Lancet Nov 2026) | 7 |
| UBT251 United Laboratories | GIP/GLP-1/GCG | s.c. | United Laboratories (Novo Nordisk licence) | phase 3 | Phase 3 in China: UNIGUIDE-1 (T2D) recruiting since Sep 2026; obesity and sleep apnoea trials registered; phase 2 (T2D) at EASD 2026 | 8 |
| VK2735 Viking Therapeutics | GIP/GLP-1 | s.c. / oral | Viking Therapeutics | phase 3 | Phase 3: s.c. VANQUISH-1/-2 (since 2025); oral SUNRISE-1/-2 started Oct 2026 (obesity with and without T2D); VENTURE s.c. phase 2 published (Obesity 2026) | 5 |
| Zovaglutide ZT002, QL Biopharm | GLP-1 (ultra-long-acting, monthly) | s.c. | QL Biopharm | phase 3 | Phase 3 in obesity (HORIZON-1, China, started Jan 2026) | 0 |
| CT-996 Roche / Carmot | GLP-1 (small molecule) | oral | Roche | phase 2 | Phase 2 | 0 |
| Cotadutide MEDI0382, AstraZeneca | GLP-1/GCG | s.c. | AstraZeneca | phase 2 | Phase 2 (MASH, CKD with T2D) completed; no phase 3 registered | 0 |
| Dapiglutide ZP7570, Zealand | GLP-1/GLP-2 | s.c. | Zealand Pharma | phase 2 | Phase 2 | 0 |
| Efinopegdutide MK-6024 | GLP-1/GCG | s.c. | MSD (Hanmi) | phase 2 | Phase 2b MASH | 0 |
| Efocipegtrutide HM15211, Hanmi | GIP/GLP-1/GCG | s.c. | Hanmi | phase 2 | Phase 2 in biopsy-confirmed MASH | 0 |
| HEC88473 HEC | GLP-1/FGF21 | s.c. | HEC | phase 2 | Phase 2 | 0 |
| HRS-4729 Hengrui | GIP/GLP-1/GCG | s.c. | Hengrui | phase 2 | Phase 2 master protocol in MASH recruiting since Aug 2026; phase 1 at EASD 2026 | 1 |
| Macupatide LY3532226, Eli Lilly | GIP | s.c. | Eli Lilly | phase 2 | Phase 2 (alone and with eloralintide) | 0 |
| RGT-075 Regor | GLP-1 (small molecule) | oral | Regor | phase 2 | Phase 2b (36 weeks) presented at EASD 2026 | 1 |
| ASC35 / ASC36 Ascletis | GIP/GLP-1 + amylin (monthly co-formulation) | s.c. monthly | Ascletis | phase 1 | Phase 1 single and multiple ascending dose study recruiting since Aug 2026; preclinical data at EASD 2026 | 0 |
| Albiglutide Tanzeum (withdrawn) | GLP-1 | s.c. | GSK | — | Withdrawn from market (2018) despite positive CVOT | 0 |
| DD1013 Huadong | GLP-1 + GIP + amylin (triple) | s.c. | Huadong Medicine | preclinical | Preclinical (EASD 2026) | 0 |
| Dulaglutide Trulicity | GLP-1 | s.c. | Eli Lilly | — | Approved (T2D); not developed for obesity | 0 |
| Efpeglenatide Hanmi / Sanofi | GLP-1 | s.c. | Hanmi | — | Positive CVOT (AMPLITUDE-O); development paused | 0 |
| Exenatide Bydureon / Byetta | GLP-1 | s.c. | AstraZeneca | — | Approved (T2D) | 0 |
| Lixisenatide Lyxumia / Adlyxin | GLP-1 | s.c. | Sanofi | — | Approved (T2D); neutral CVOT | 0 |